fr   en
Fundraisings
Select a company :
Select an investor :
Choose date:
[<<]      «      2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12      »      [23]
Date Company Amount Investors Planned use / Other
2009-11-26 ELARA Pharmaceuticals (Germany) The company was founded in 2006 as a spin-out of the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany €4.6 Million (€ 2.6 million Series A financing round, which will trigger an additional € 2 million from the BMBF GOBio and the Biotechnologie Rhein-Neckar (BioRN) Spitzencluster programs) EMBL Ventures (Germany)
Kreditanstalt für Wiederaufbau - KfW (Germany)
Wagnisfinanzierungsgesellschaft für Technologieförderung in Rheinland-Pfalz - WFT (Germany)
BMBF GOBio (Germany)
Biotechnologie Rhein-Neckar (BioRN) (Germany)
See details
2009-11-24 Oxagen (UK) £16 Million Novartis Venture Funds (Switzerland)
MPM Capital (USA)
SV Life Sciences (UK)
Advent Ventures
Bessemer Venture Partners
Omega
Abingworth (UK)
IBT
Red Abbey
The Wellcome Trust (UK)
See details
2009-11-23 Ablynx (Belgium) € 1.1 million Flemish agency for Innovation by Science and Technology (IWT) (Belgium)
See details
2009-11-20 Newron Pharmaceuticals (Italy) CHF 7.9 million (€ 5.2 million) international institutional investors See details
2009-11-20 Kinaxo Biotechnologies (Germany) undisclosed amount Leifina
Conmit Invest
Mountain Partners
BioM (Germany)
High-Tech Gründerfonds (Germany)
the Max-Planck Society (Germany)
KfW ERP Start-Fonds (Germany)
private investors (Axel Ullrich, Hellmut Kirchner, Manfred Ferber)
See details
2009-11-18 Evotec (Germany) €2.5 million Federal Ministry of Education and Research (BMBF - Germany) See details
2009-11-18 Nicox (France) € 30 million - €20 million have been subscribed by the Fonds Stratégique d’Investissement (FSI). FSI will hold 5.1% of the company’s share capital after this capital increase, making the FSI one of NicOx’s major shareholders
- other institutional investors (comprising a mix of existing shareholders and new investors)
See details
2009-11-16 4SC AG (Germany) €30 million   See details
2009-11-16 Xigen (Switzerland) $20 Million Tilocor Life Science (Switzerland) See details
2009-11-11 Cellerix (Spain) €27 million YSIOS Capital Partners (Spain)
LSP (Life Science Partners - Netherlands-Germany-USA)
Ventech (France)
Grupo Genetrix (Spain)
Roche Venture Fund (Switzerland)
Novartis Venture Fund (Switzerland)
Bankinter S.A. (Spain)
Capital Riesgo Madrid (Spain)
JV Risk Technologies S.L.
See details
2009-11-03 Santhera Pharmaceuticals (Switzerland) CHF 1 million Association Française contre les Myopathies(AFM)/French Muscular Dystrophy Association - France See details
2009-11-03 arGEN-X (The Netherlands) €1.3 million Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)

See details
2009-11-03 CEVEC Pharmaceuticals (Germany) € 4 million Creathor Venture Fonds (Germany)
NRW.BANK (Germany)
Sparkasse KoelnBonn (Germany)
KfW bank (Germany)
See details
2009-11-02 Probiodrug (Germany) € 36 million Biogen Idec New Ventures (USA)
BB Biotech (Switzerland)
Edmond de Rothschild Investment Partners (France)
LSP Life Science Partners (The Netherlands)
IBG Fonds
TVM Capital (Germany)
HBM BioVentures (Switzerland)
CFH Group (Denmark)
private investors
See details
2009-11-02 GTC Biotherapeutics (USA) $10 million LFB Biotechnologies (wholly owned subsidiary of LFB S.A. - France) See details
[<<]      «      2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12      »      [23]